APOB Genotype (p.Gln3432Glu)

ApoB (apolipoprotein B) is the main protein on LDL particles, the particles that carry cholesterol into artery walls. This test reads one letter in the APOB gene, known as rs1042023. A change at this letter swaps one building block of the apoB protein, glutamine, for another, glutamic acid, at position 3,432. Scientists write it as p.Gln3432Glu or Q3432E.

Your report lists this variant under high cholesterol as a risk factor. That is fair in a narrow sense: very large studies link it to slightly higher LDL cholesterol and apoB on average. But the effect is small, a link to heart disease has not been shown, and it does not cause familial hypercholesterolemia, the inherited condition behind markedly high LDL. Your LDL and apoB blood tests tell you far more than this result.

What ApoB Does

Every LDL particle, and every VLDL, remnant and Lp(a) particle, carries exactly one apoB molecule, so measuring apoB counts these particles. Cholesterol can only enter the artery wall inside apoB particles. ApoB is also the part of LDL that LDL receptors on cells grab to pull LDL out of the blood. When apoB cannot bind properly, LDL is cleared slowly and cholesterol builds up in the blood. Researchers first showed this in 1987, in a family with an inherited apoB defect.

What This Variant Changes

The change sits in the stretch of apoB that was long thought to bind the LDL receptor. Glutamic acid carries a negative electrical charge that glutamine does not, which led researchers in the 1990s to ask whether the swap weakens LDL's grip on its receptor. Older papers count apoB's building blocks starting 27 places later, after a short leading piece that is cut off, so they call this same change Q3405E.

The early lab studies did not agree:

• No effect found (1996): LDL from 7 people with one copy, and from 1 woman with two copies, bound the LDL receptor normally.
• No link found (1997): in more than 800 people with high LDL or coronary artery disease, the variant was not linked to faulty receptor binding, high cholesterol or coronary disease.
• A small effect found (1998): among 928 people with high blood fats, about 1.4 percent carried the variant, and carriers' LDL supported only about 77 percent of normal growth in a cell test that depends on LDL binding its receptor.

These were small studies from before large genetic databases existed, and they could not settle whether the variant has a small effect on LDL.

What the Large Studies Show

Much larger studies have since given a clearer answer. Several analyses of the UK Biobank, each covering roughly 355,000 to 431,000 people, linked the variant to higher LDL cholesterol, apoB and total cholesterol, with statistical evidence far beyond chance. Fine-mapping, a method that sorts out which of several neighboring letters is behind a signal, points to this letter itself as the likely cause.

The average effect is small. In the Pan-UK Biobank analysis of about 400,000 people, each copy was linked to LDL cholesterol about 0.15 mmol/L (about 6 mg/dL) higher, after accounting for cholesterol-lowering medicines. That is roughly one-sixth of the usual spread in LDL between people. A separate analysis of 405,088 UK Biobank participants found total cholesterol about 0.08 standard deviations higher per copy. In FinnGen, a study of about 500,000 Finns, carriers had about 21 percent higher odds of using a statin and about 12 percent higher odds of a high-cholesterol diagnosis, which fits a modest rise in LDL. Why the variant nudges LDL up is not settled.

Heart Disease: What Is Known and What Is Not

LDL causes artery disease, and genetic and trial evidence shows that the risk from LDL rises with both how much higher it is and how long it stays higher. A small lifelong rise in LDL could therefore add a small amount of risk. For this variant, though, that has not been shown. The direct evidence so far:

• UK Biobank (about 400,000 people): carriers were not detectably more likely to have had a heart attack (12,038 people with heart attacks were included), coronary artery disease or ischemic heart disease.
• FinnGen (about 500,000 Finns): carriers were slightly more likely to have several coronary diagnoses: angina (about 14 percent higher odds), coronary atherosclerosis (about 9 percent) and ischemic heart disease (about 6 percent). These signals were modest, FinnGen tested thousands of conditions so some chance findings are expected, the UK Biobank did not confirm them, and heart attack itself showed no clear link.
• A 1997 study of more than 800 patients: no link with coronary artery disease.

Put together: this variant nudges LDL up slightly, and whether it measurably raises heart risk is not established. The studies so far can neither confirm nor rule out the small extra risk that a slightly higher lifelong LDL could bring. Your actual LDL cholesterol and apoB, along with blood pressure, smoking and blood sugar, are what guide prevention, not this result.

Not the Same as Familial Hypercholesterolemia

Familial hypercholesterolemia (FH) is an inherited condition in which a rare gene change markedly raises LDL cholesterol and the risk of artery disease. One form, familial defective apoB, comes from a small number of APOB changes that stop LDL binding its receptor properly. One of these is p.Arg3527Gln, called R3500Q in older papers, which ClinVar classifies as pathogenic, meaning it causes disease.

p.Gln3432Glu is different. ClinVar, the US public database of variant classifications, lists it as benign or likely benign for FH and related conditions, with all 19 submissions (labs and research groups) agreeing and no conflicts. None of them classifies it as a risk factor, and one lab noted that it is too common in people of European ancestry to be the cause of a rare inherited disease. So this result does not mean you have FH.

It also cannot rule FH out, because this test reads only one letter. If your LDL is very high, or high cholesterol or early heart disease runs strongly in your family, talk with your doctor about whether a fuller evaluation makes sense.

How Common It Is

This variant is uncommon but not rare. In the gnomAD v4 reference database, just under 1 percent of all APOB gene copies carry it (0.95 percent in the exome data, 0.67 percent in the genome data). It is about 1.1 percent in people of non-Finnish European ancestry, which works out to roughly 1 in 45 carrying one copy, and about 1 percent in Finns. It is less common in people of Latin American (about 0.5 percent), South Asian (about 0.2 percent) and African ancestry (about 0.1 to 0.2 percent), and it was not seen in people of East Asian ancestry. NCBI's ALFA project gives similar figures: 0.93 percent overall and 1.01 percent in Europeans. Two copies are rare, about 1 in 9,000 people in gnomAD.

How Results Are Reported

Your report shows the two letters you carry at this spot, one from each parent, printed on the forward strand of chromosome 2 (position 21,006,574 on the current GRCh38 reference, 21,229,446 on the older GRCh37). The APOB gene is read from the opposite strand, so scientific papers and ClinVar write the same change with the matching opposite letters, as c.10294C>G. On your report, G is the usual version and C is the variant.

The large studies estimated the effect per copy, assuming each copy adds a similar amount. What this means for you: none of these results is a diagnosis, and your blood tests show where you actually stand.

Why You Only Need This Test Once

Your DNA does not change, so your rs1042023 genotype at 25 will be the same at 65. What changes over time, and what is worth tracking, is your LDL cholesterol and apoB.

What to Do With Your Result

Whatever your genotype, the practical steps are the same:

• Know your LDL cholesterol and apoB: these blood tests measure the particles that drive artery disease; this genotype only hints at a small average nudge.
• Do not read one copy as a diagnosis: this variant does not cause familial hypercholesterolemia, and labs classify it as benign or likely benign.
• Do not read G/G as an all-clear: most people with high LDL do not carry this variant; only your blood tests show your levels.
• Talk with your doctor if your LDL is high or heart disease runs in your family: your doctor can weigh your blood results, family history and other risks, and decide whether more testing makes sense.

Carrying this variant is uncommon but not rare, and on average it nudges LDL up a little. It is a small piece of your cholesterol genetics; your blood tests are what guide care.